About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ZIAGEN® Post-marketing Surveillance | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01205243

ZIAGEN® Post-marketing Surveillance

An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and efficacy of ZIAGEN® administered in Korean patients according to the prescribing information...

Lead sponsor: ViiV Healthcare•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators

GlaxoSmithKline

This study will collect clinical data, mainly focused on safety, in Korean population as per the requirement of KFDA for market authorization. ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All subjects must satisfy the following criteria.
•Subject who is treated in combination with other antiretroviral agents for the treatment of HIV infection.
•Subject who is considered to follow this post marketing surveillance protocol by the investigator.

Exclusion Criteria

•Subjects with hypersensitivity to ZIAGEN® or ingredients
•Subjects with moderate or severe hepatic impairment
•Subject with end-stage renal disease

Related studies

COMPLETEDPhase 3

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577 · Infection, Human Immunodeficiency Virus I, HIV Infection

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

NCT03327740 · Infection, Human Immunodeficiency Virus I

COMPLETEDPhase 3

Fosamprenavir Versus Other Protease Inhibitors

NCT00094523 · Infection, Human Immunodeficiency Virus I

COMPLETEDPhase 3

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

NCT01263015 · Infection, Human Immunodeficiency Virus I

COMPLETEDPhase 3

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

NCT00242840 · Infection, Human Immunodeficiency Virus I, HIV Infection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 19, 2018Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment671

Start dateNov 2010

Last updatedJun 19, 2018

Condition

Infection, Human Immunodeficiency Virus I

Locations shown

GSK Investigational Site

Incheon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 19, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions